Channel: mTOR and rapamycin

Inspired by: David M. Sabatini

Sirolimus, also known as rapamycin and sold under the brand name Rapamune among others, is a macrolide compound that is used to coat coronary stents, prevent organ transplant rejection, treat a rare lung disease called lymphangioleiomyomatosis, and treat perivascular epithelioid cell tumor (PEComa). It has immunosuppressant functions in humans and is especially useful in preventing the rejection of kidney transplants. It is a mechanistic target of rapamycin kinase (mTOR) inhibitor that inhibits activation of T cells and B cells by reducing their sensitivity to interleukin-2 (IL-2). Wikipedia (CC BY-SA 3.0)

    2023 Articles

    31 781 articles

    mTORC1 implicated in Still’s disease and MAS

    Comment Section

    Effects of STAU1/staufen1 on autophagy in neurodegenerative diseases

    Comment Section

    PI5P4Kα: a target in prostate cancer?

    Comment Section

    Mitochondrial fission fueled by fasting

    Comment Section

    Correction: RhoA promotes osteoclastogenesis and regulates bone remodeling through mTOR-NFATc1 signaling

    Comment Section

    CORRECTION

    Comment Section

    The translation m(o)TOR that propels regeneration

    Comment Section

    GATOR2 rings GATOR1 to speak to mTORC1

    Comment Section

    Transcriptional regulation of autophagy by chromatin remodeling complex and histone variant

    Comment Section

    Transcriptional response of endometrial cells to Insulin, cultured using microfluidics

    • Soo Young Baik, Alisha Maini, Haidee Tinning, …, Daman Adlam, Peter T Ruane, Niamh Forde
    • Reprod Fertil, 10.1530/raf-21-0120
    Comment Section

    2022 Articles

    3 610 articles

    mTOR inhibitors in a patient with lupus nephritis; why not?

    Comment Section

    mTORC1 takes control of lysosomal lipid breakdown

    • Laura Tribouillard, Laura Tribouillard, Laura Tribouillard, …, Mathieu Laplante, Laura Tribouillard, Mathieu Laplante
    • Nat Metab, 10.1038/s42255-022-00702-w
    Comment Section

    Queueing theory model of mTOR complexes’ impact on Akt-mediated adipocytes response to insulin

    • Sylwester M Kloska, Krzysztof PaƂczyƄski, Tomasz Marciniak, …, Paul H Davis, Ghada A Soliman, Tadeusz A Wysocki
    • PLoS One, 10.1371/journal.pone.0279573
    Comment Section

    Phosphorylation of the novel mTOR substrate Unkempt regulates cellular morphogenesis

    • Pranetha Baskaran, Simeon R Mihaylov, Elin Vinsland, …, Andrew R Tee, Jernej Murn, Joseph M Bateman
    • J Biol Chem, 10.1016/j.jbc.2022.102788
    Comment Section

    Immunohistochemical Techniques for Phosphoproteins

    • Berenice L Sanz Ressel, Alfredo A Molinolo, Berenice L Sanz Ressel, Alfredo A Molinolo, Berenice L Sanz Ressel, Alfredo A Molinolo
    • Methods Mol Biol, 10.1007/978-1-0716-2811-9_17
    Comment Section

    mTOR Signaling Network in Cell Biology and Human Disease

    • Jane J Yu, Elena A Goncharova, Jane J Yu, …, Elena A Goncharova, Jane J Yu, Elena A Goncharova
    • Int J Mol Sci, 10.3390/ijms232416142
    Comment Section

    Ring domains are essential for GATOR2-dependent mTORC1 activation

    Comment Section

    Discovery of small molecule mechanistic target of rapamycin inhibitors as anti-aging and anti-cancer therapeutics

    • Zofia Chrienova, David Rysanek, Patrik Oleksak, …, Kamil Kuca, Zdenek Hodny, Eugenie Nepovimova
    • None, 10.3389/fnagi.2022.1048260
    Comment Section

    Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors

    • G Leslie Burnett, Yu C Yang, James B Aggen, …, Mallika Singh, Jacqueline A M Smith, Adrian L Gill
    • J Med Chem, 10.1021/acs.jmedchem.2c01658
    Comment Section

    Ras-mediated activation of mTORC2 promotes breast epithelial cell migration and invasion

    • Shannon E Collins, Mollie E Wiegand, Alyssa N Werner, …, Douglas J Swango, Ghassan Mouneimne, Pascale G Charest
    • Mol Biol Cell, 10.1091/mbc.e22-06-0236
    Comment Section